Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. - Wikidata - awgldk - TriplyDB

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.

http://www.wikidata.org/entity/Q34084020

about

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis Dry eye: an inflammatory ocular disease Jakpot! New small molecules in autoimmune and inflammatory diseases Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma.Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunction Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.Update on Janus kinase antagonists in inflammatory bowel disease.Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).An N-ethyl-N-nitrosourea (ENU)-induced dominant negative mutation in the JAK3 kinase protects against cerebral malaria Tofacitinib for the treatment of rheumatoid arthritis.JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials.Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.Expression of hedgehog signal pathway in articular cartilage is associated with the severity of cartilage damage in rats with adjuvant-induced arthritis.A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study.Development and validation of a RP-HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study.The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis.Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial Tofacitinib.Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.

P2860

Q26765028-987F6674-BD18-4917-8DA8-F270BE400A05 Q26823326-D2C58730-FA1F-4EFB-98B1-CE679B0D2F66 Q26852044-86B7D3B9-2760-47C9-A4EA-6A5A10488636 Q27001957-5EBE895A-CB72-49D5-8FD1-BF154EB2083F Q27015831-CF66E75C-53EC-4819-9CED-AC622230FE60 Q28552367-8D5323D6-C000-43A6-ABBD-415C48245F3B Q28674280-06BD51FD-D978-468D-A116-0B2B8F960DC8 Q30313903-12E8F2A0-060C-46C8-947D-DEFF2A188BE6 Q33578361-5E5581DE-42F3-42E5-AC20-3B5C5A80D7EA Q33703161-85112EA3-C185-43B2-8233-F2A3ED0D3EAC Q33752141-F512E009-2669-4030-BEC2-FB7970622E69 Q33775184-2F1F1F9D-80B1-4624-9211-6603DE042D58 Q33837678-4457B12A-C3C5-41F1-9E0E-6AB6EE64268A Q34030650-74A6C6DB-3FEA-4FDC-893B-79230376B3B6 Q34122846-AA9DA87B-AC5C-41A0-91BB-16E3EA736240 Q34169114-0452A17D-6FB5-41F9-8E2E-52DA8F65EAA9 Q34170436-4ECA8D6E-7326-4A53-96AA-32AA25A21229 Q34275878-699D3B57-D5C3-4BBD-A37D-0B5FB07F16A0 Q34276089-B278EBD8-2DCA-44BE-890A-6F5CCDD7677A Q34402215-5EDC1116-FD0E-4BD9-946B-8720EF45B94E Q34454531-E589D744-4DFE-44CA-B797-84AB2E50412C Q34851473-24B1CCC2-85BA-418E-A61D-B4E6718A98F7 Q35226203-A9AC7702-D269-4B36-9C27-EDDE2A89E7D6 Q35314876-ACE9490D-DA18-45A8-AD6F-FF7F5DF82C2B Q35549450-0C10EEDE-16FE-4E0E-AF60-AA5AFF57E5B1 Q35605477-BDAE3303-F7C9-406F-8065-CAA628B10355 Q35834909-383C6937-EBB4-4079-8D53-52CAF8ACEBB5 Q36246592-F0F406EC-B704-48BE-953E-894BC75CC525 Q36513512-EF332B1A-1BA7-4CE9-A9AD-90E5B8FC48ED Q36761766-91366714-3DC8-4BF6-8F32-1D9EB328F2BC Q36968737-294457FD-AAE9-4E88-AAFC-8A2C14F5E19A Q37031284-571EC530-8A11-42A7-8E74-AB46F16C8908 Q37142451-6272A75C-DD5D-4ED4-9EE6-C330084822B1 Q37148745-B1EF783E-FDE6-4C1A-95CE-E891D447507F Q37257476-ACCF7CA6-C9B4-4BC5-A6F8-0A4EC29BE830 Q37311533-526AB6D1-EF01-4984-9233-92BBAE9F3B5D Q37312668-5D130710-AA96-4924-9276-BEA6959F06EA Q37340011-20CE526A-1854-465C-97B2-3ED3A3D0F9EA Q37420530-F264D259-5F39-421C-B9FE-5D41F6A9A858 Q37461886-5E5815CA-9211-47D5-BFE5-1A7AFC19C9A3

P2860

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.

http://www.wikidata.org/entity/Q34084020

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@ast

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@en

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@nl

type

label

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@ast

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@en

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@nl

prefLabel

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@ast

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@en

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@nl

P1433

Q34084020-B8B6EB95-B377-418C-918E-2FBFD9B9A2E4

P1476

Q34084020-F2507F02-F100-4677-9F6B-512C930FA77E

P2093

Q34084020-32EFC74F-99CB-4DA3-9E0A-877EF7C5E9DB

Q34084020-3CEE088C-DD38-4A7A-9A0A-E4DA54C3369E

Q34084020-46BF02DB-B7C7-468D-958A-49764CCFE911

Q34084020-4C7B4236-2FF5-4C91-8807-1E75DD02490C

Q34084020-56917314-7C6B-45CA-85B0-9E035A308651

Q34084020-65B82C57-4DB1-4EAD-81CA-38D6A1E66CF0

Q34084020-703792DA-80EF-4F8A-8834-ADFF91B3ABE2

Q34084020-87FD0910-4A54-4976-9297-460F85AF3613

Q34084020-9E633B50-2646-44ED-8CBE-B1C86E82F39C

Q34084020-A99EA1AB-7308-4069-A135-C93502FF1B75

P2860

Q34084020-075912A1-91C6-4786-B043-CAE857B9ECC6

Q34084020-0779D1E9-F35F-4856-AFB0-A3A1BC03A742

Q34084020-09373C90-B663-4400-968F-85171B16571F

Q34084020-09F6C828-E64C-47E1-B928-BBC75876D9F2

Q34084020-0BE1BF3B-88DB-4D85-AFA2-E275D15CA161

Q34084020-0FA44068-CF2C-43B5-A030-A7062132750C

Q34084020-1231CA17-BD2E-486A-9633-9837B0D1A49C

Q34084020-13D74126-D7EC-45F7-A7AD-263A9767C324

Q34084020-1A57D671-BECC-4B88-B229-A831CCA92024

Q34084020-286508B7-EA4B-42D8-9F79-CBE7284E9760

P2888

Q34084020-3975A84F-424A-41BE-8DD5-7625CDB25028

P304

Q34084020-51700530-1C16-41FB-B0DA-D1554327B905

P31

Q34084020-DE07122F-0C6B-4B37-B90E-ABA5FDAA0688

P356

Q34084020-D07349A2-B5F9-4FED-BA01-26A4A9A8C22B

P478

Q34084020-BCA0C67A-254F-45FF-ABE5-12655527C337

P577

Q34084020-3C95AD0C-62F5-4318-BD1D-70657BA0EC29

P5875

Q34084020-D97C137F-6151-442A-8E6A-17034144EE05

P6179

Q34084020-91F675F9-34A3-482D-BB1E-71701E2A55F4

P698

Q34084020-4FC0F693-27AC-4C84-B748-9798A5EF0CAB

P932

Q34084020-1BBC21C8-EDE4-4018-B137-1D7D7F15455D

P356

P1433

Journal of Inflammation

P1476

Anti-inflammatory activity and ...... at adjuvant-induced arthritis.

@en

P2093

Christie L Funckes-Shippy

http://www.w3.org/2001/XMLSchema#string

Cindy J Gross

http://www.w3.org/2001/XMLSchema#string

Dale L Morris

http://www.w3.org/2001/XMLSchema#string

Debra M Meyer

http://www.w3.org/2001/XMLSchema#string

James D Warner

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Hirsch

http://www.w3.org/2001/XMLSchema#string

Jennifer L Barks

http://www.w3.org/2001/XMLSchema#string

Martin E Dowty

http://www.w3.org/2001/XMLSchema#string

Matthew J Saabye

http://www.w3.org/2001/XMLSchema#string

Michael I Jesson

http://www.w3.org/2001/XMLSchema#string

P2860

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

Selectivity and therapeutic inhibition of kinases: to be or not to be?

Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation.

A quantitative analysis of kinase inhibitor selectivity

Jak2 is essential for signaling through a variety of cytokine receptors

Enhanced neutrophilic granulopoiesis in rheumatoid arthritis. Involvement of neutrophils in disease progression.

Implication of granulocyte-macrophage colony-stimulating factor induced neutrophil gelatinase-associated lipocalin in pathogenesis of rheumatoid arthritis revealed by proteome analysis.

Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.

Interleukin-6 and chronic inflammation

P2888

P304

41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-9255-7-41

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45628711

http://www.w3.org/2001/XMLSchema#string

P6179

1023050699

http://www.w3.org/2001/XMLSchema#string

P698

20701804

http://www.w3.org/2001/XMLSchema#string

P932

2928212

http://www.w3.org/2001/XMLSchema#string